HCP Live December 29, 2024
Key Takeaways
- 2024 saw FDA approvals for new therapies in UC, CD, EoE, and GERD, expanding treatment options significantly.
- The AGA released guidelines on fecal microbiota-based therapies and cyclic vomiting syndrome, providing updated clinical practice guidance.
- Key FDA approvals included dupilumab for pediatric EoE, budesonide oral suspension for EoE, and vonoprazan for non-erosive GERD.
- Novel noninvasive colorectal cancer screening tests, including ColoSense and Guardant Health’s Shield blood test, were approved, enhancing screening options.
This year in review spotlights top GI FDA news from 2024 and new clinical guidance from the American Gastroenterological Association.
2024 has been a landmark period for gastroenterology, defined by groundbreaking FDA approvals across a multitude of disease states and pivotal updates in clinical practice...
Today's Sponsors
Today's Sponsor